BridgeMD
Clinical trial of MK-7648A in adults and children with skin cancer
EU CTIS ID: 2022-501417-31-00
What this study is testing
To compare MK-7684A to pembrolizumab with respect to RFS
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Has surgically resected and histologically or pathologically confirmed diagnosis of Stage IIB and IIC (pathological or clinical), III, or IV cutaneous melanoma per the American Joint Committee on Cancer (AJCC) eighth edition guidelines
- Has not received any prior systemic therapy for melanoma beyond surgical resection
- Has had no more than 12 weeks between final surgical resection and randomization
- Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy (ART)
You likely can't join if
- Has ocular, mucosal, or conjunctival melanoma
- Has an active autoimmune disease that has required systemic treatment in past 2 years
- Has an active infection requiring systemic therapy
- Has known concurrent active Hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) and Hepatitis C virus (defined as HCV ribonucleic acid [RNA] qualitative is detected) infection
- Has had an allogenic tissue/solid organ transplant
- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication
See the full eligibility criteria
- Has surgically resected and histologically or pathologically confirmed diagnosis of Stage IIB and IIC (pathological or clinical), III, or IV cutaneous melanoma per the American Joint Committee on Cancer (AJCC) eighth edition guidelines
- Has not received any prior systemic therapy for melanoma beyond surgical resection
- Has had no more than 12 weeks between final surgical resection and randomization
- Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy (ART)
- Has ocular, mucosal, or conjunctival melanoma
- Has an active autoimmune disease that has required systemic treatment in past 2 years
- Has an active infection requiring systemic therapy
- Has known concurrent active Hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) and Hepatitis C virus (defined as HCV ribonucleic acid [RNA] qualitative is detected) infection
- Has had an allogenic tissue/solid organ transplant
- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication
- Has not adequately recovered from major surgical procedure or has ongoing surgical complications
- Has received prior radiotherapy within 2 weeks of start of study intervention or has had a history of radiation pneumonitis
- Received a live or live attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed
- Has received an investigational agent or has used an investigational device within 4 weeks before study intervention administration
- Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
- Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
- Has a history of central nervous system (CNS) metastases and/or carcinomatous meningitis
The study team makes the final eligibility decision.
Where it's taking place
- Turkey
- India
- South Africa
- Korea, Republic of
- Israel
- Chile
- Colombia
- New Zealand
- Canada
- Brazil
- United Kingdom
- Argentina
- China
- Australia
- Japan
- Switzerland
- United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years, 0-17 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Turkey; India; South Africa; Korea, Republic of; Israel; Chile and 11 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.